Fidia completed the acquisition of the controlling stake in Meditrina.

Fidia, a company specializing in innovative hyaluronic acid-based pharmaceutical and specialty products, completed the acquisition of a majority stake in Meditrina, a Romanian distributor of medical devices, pharmaceuticals and cosmetics in urology, gynaecology, and dermatology. Financial terms were not disclosed. “We are focusing our investments in markets with high potential, with the aim of strengthening our global presence and expanding into new therapeutic areas. The expansion of our product portfolio and access to complementary channels enable us to affirm our position and offer increasingly effective solutions to meet patient needs,” Carlo Pizzocaro, Fidia President & CEO.